Association of Tumor Protein 53 Polymorphism with Esophageal Cancer Cases: A Systematic Review and Meta-Analysis

Abstract

To investigate the association between tumor protein 53 polymorphism and esophageal cancer cases using systematic review and meta-analysis, this provides a basis for future researches. All studies on tumor protein 53 mutations in patients with esophageal cancer and its influencing factors, which published before May 2021, were collected by searching Cochrane Library, PubMed, Embase, China National Knowledge Infrastructure and Wanfang data. Meta-analysis was performed using RevMan 5.3. Ten eligible studies (Chinese n=7, English n=3) involving 1379 cases were included in this analysis. Meta-analysis showed that the odds ratio value (95 % confidence interval) of tumor protein 53 mutations in Caucasian patients with esophageal cancer was 70.51 (9.77, 508.88), z=4.22, p<0.0001; the odds ratio value (95 % confidence interval) of tumor protein 53 mutations in Chinese Han patients with esophageal cancer was 1.06 (0.63, 1.79), z=0.22, p=0.83; the odds ratio value (95 % confidence interval) of tumor protein 53 mutations in Chinese Uyghur patients with esophageal cancer was 18.48 (4.44, 76.90), z=4.01, p<0.0001. The odds ratio value (95 % confidence interval) of tumor protein 53 mutations in patients with esophageal cancer was 1.01 (0.60, 1.72), z=0.05, p=0.96; the odds ratio value (95 % confidence interval) of tumor protein 53 deletions in patients with esophageal cancer was 23.02 (9.04, 58.63), z=6.57, p≤0.00001. There was no significant difference in tumor protein 53 mutations between patients with esophageal cancer and the control group. There is a certain correlation between tumor protein 53 polymorphism and the incidence of esophageal cancer and the change of tumor protein 53 gene will affect the risk and prognosis of esophageal cancer.